DEFA14A ·Filed Jun 1, 2026

CABA

Cabaletta Bio, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed4mo ago SEC0001193125-26-249726
Proxy solicitation materials
Actionable Insight • Neutral

The withdrawal is a procedural change with no immediate financial impact. Monitor for any future proxy filing regarding a revised equity plan proposal. The annual meeting proceeds as scheduled with the remaining proposals.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
CABA ▼ -12.26% at T+60d
NEUTRAL call ✗ call lost -12.26% · α vs SPY -13.49% · entry $3.67 → $3.22
Entry anchored
Jun 1, 2026
via day open
T+1d
+0.27%
call +0.27% · α +0.13%
$3.68
settled 4mo ago
T+5d
-11.44%
call -11.44% · α -8.69%
$3.25
settled 4mo ago
T+20d
-15.26%
call -15.26% · α -13.96%
$3.11
settled 3mo ago
T+60d
-12.26%
call -12.26% · α -13.49%
$3.22
settled 5w ago

Price Chart

Loading chart...

Executive Summary

Cabaletta Bio's board withdrew Proposal 3 (amendment to the 2019 Stock Option and Incentive Plan) from the June 9, 2026 annual meeting agenda, citing further review. The remaining five proposals (director elections, ratification of auditor, say-on-pay, etc.) will proceed as scheduled. Existing proxy cards remain valid; no new voting instructions are needed.

Key Facts

  • Proposal 3 (amendment to 2019 Stock Option and Incentive Plan) withdrawn from the 2026 annual meeting agenda.
  • Board determined on May 31, 2026, not to seek stockholder approval of Proposal 3.
  • All other proposals (1, 2, 4, 5, 6) remain on the agenda for the June 9, 2026 meeting.
  • Record date remains April 20, 2026; existing proxy cards remain valid without resubmission.
  • Company reserves right to propose future amendments to the equity compensation plan.

Financial Impact

No direct financial impact; removal of equity plan vote removes potential dilution from future option grants, but no dollar amounts disclosed.

dilution

Risk Factors

  • Potential future dilution if a revised equity plan is proposed later.
  • No material risk from this filing alone.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
81% bullish (16 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001193125-26-249726
Document: 0001193125-26-249726-index-headers.html0001193125-26-249726
Document: 0001193125-26-249726-index.html0001193125-26-249726
Document: 0001193125-26-249726.txt0001193125-26-249726
17 reports for CABA
Performance horizon
75% Hit rate 6 of 8 directional calls best @ T+60▲ +31.59%May 4, 2026
Filters
Rows
Reports for CABA — sortable, filterable
TypeNow
Sep 14, 2026
18d ago
8-K
NEUTRAL ★ 4/10
$2.91 $2.46▼ −15.46%▼ −15.57%$1.88 (−35.57%)
Aug 15, 2026
6w ago
Institutional Cluster
BULLISH ★ 5/10
$2.89 $3.10▲ +7.27%▲ +8.46%$1.88 (−35.12%)
Aug 13, 2026
7w ago
8-K
NEUTRAL ★ 4/10
$2.71 $3.19▲ +17.71%▲ +19.68%$1.88 (−30.81%)
Aug 13, 2026
7w ago
Press Release
NEUTRAL ★ 4/10
$2.71 $3.19▲ +17.71%▲ +19.68%$1.88 (−30.81%)
Jun 11, 2026
16w ago
Institutional Cluster
NEUTRAL ★ 5/10
$3.01 $2.84▼ −5.65%▼ −6.32%$1.88 (−37.71%)
Jun 3, 2026
17w ago
8-K
BULLISH ★ 7/10
$3.58 $3.04▼ −15.08%▼ −11.26%$1.88 (−47.63%)
Jun 1, 2026
17w ago
DEFA14A
NEUTRAL ★ 3/10
$3.67 $3.25▼ −11.44%▼ −8.69%$1.88 (−48.91%)
May 14, 2026
20w ago
8-K
BEARISH ★ 6/10
$3.61 $3.69▼ −2.22%▼ −2.93%$1.88 (+48.06%)
May 14, 2026
20w ago
Press Release
NEUTRAL ★ 4/10
$3.61 $3.69▲ +2.22%▲ +2.93%$1.88 (−48.06%)
May 14, 2026
20w ago
8-K
BULLISH ★ 7/10
$3.61 $3.69▲ +2.22%▲ +2.93%$1.88 (−48.06%)
Showing 10 of 17

US Market Status

Market Open — Closes in 1h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access